The Review Of
DIABETIC
STUDIES OPEN ACCESS

Herbal Medicine For Insomnia And Mental Stress/Anxiety An Expanded Evidence-Based Review Of Phytotherapeutic Interventions

Banu S. V[1], Dr. Shiju .C[2]

[1]Principal investigator, Associate Vice president Corporate Research and Development Centre, HLL Lifecare Ltd. Akkulam, Thiruvananthapuram.
[2]Coinvestigator, Scientist Corporate Research and Development Centre, HLL Lifecare Ltd. ,Akkulam, Thiruvananthapuram.

Abstract
Insomnia and anxiety disorders are among the most prevalent neuropsychiatric conditions worldwide, significantly impairing quality of life, cognitive performance, and overall health outcomes. Although conventional pharmacotherapy—including benzodiazepines, non-benzodiazepine hypnotics, and selective serotonin reuptake inhibitors (SSRIs)—remains the primary treatment approach, long-term use is frequently limited by tolerance, dependency, withdrawal phenomena, and adverse effects.
Herbal medicine (phytotherapy) offers a complementary and integrative therapeutic alternative characterized by multi-target pharmacodynamics and generally favorable safety profiles. This expanded evidence-based review critically evaluates major medicinal plants with documented anxiolytic and sedative properties, including Withania somnifera, Valeriana officinalis, Passiflora incarnata, Bacopa monnieri, and Matricaria chamomilla. Mechanisms of action, phytochemical constituents, clinical trial evidence, safety considerations, and future research directions are systematically discussed. Current evidence supports their adjunctive use in mild-to-moderate insomnia and anxiety, although large-scale randomized controlled trials are still required.

Keywords: Insomnia; Anxiety; Herbal Medicine; Phytotherapy; Adaptogens; GABAergic modulation; HPA axis; Evidence-based herbal therapy.

1. INTRODUCTION

Insomnia is a multifactorial sleep disorder characterized by persistent difficulty in sleep initiation, maintenance, consolidation, or early morning awakening despite adequate opportunity for sleep, resulting in significant daytime impairment [1]. According to the American Psychiatric Association, chronic insomnia is diagnosed when symptoms occur at least three times weekly for a duration exceeding three months and produce measurable psychosocial dysfunction [2]. Anxiety disorders, including generalized anxiety disorder (GAD), panic disorder, and stress-related syndromes, represent a spectrum of neuropsychiatric conditions marked by excessive worry, autonomic hyperactivity, and cognitive dysregulation [3]. Epidemiological data indicate a high degree of comorbidity between insomnia and anxiety, suggesting shared pathophysiological substrates rather than independent disease processes [4].

Contemporary neurobiological models conceptualize insomnia and anxiety as disorders of hyperarousal involving dysregulation across neuroendocrine, neurotransmitter, and inflammatory pathways. Chronic psychological stress induces sustained activation of the hypothalamic–pituitary–adrenal (HPA) axis, resulting in prolonged cortisol secretion and circadian misalignment [5]. Elevated nocturnal cortisol levels are strongly associated with increased sleep latency, reduced slow-wave sleep, and fragmented rapid eye movement (REM) sleep architecture [6]. Persistent HPA axis activation further contributes to hippocampal remodeling, impaired emotional regulation, and increased vulnerability to anxiety disorders [7].

At the neurochemical level, reduced γ-aminobutyric acid (GABA)–mediated inhibitory tone, altered serotonergic and dopaminergic signaling, dysregulated melatonin secretion, and heightened noradrenergic activity collectively contribute to cortical hyperexcitability [8,9]. This neurochemical imbalance sustains the hyperarousal state characteristic of both chronic insomnia and anxiety. In

parallel, emerging evidence implicates neuroinflammatory processes and oxidative stress as mechanistic contributors. Elevated circulating cytokines such as interleukin-6 (IL-6) and tumor necrosis factor-α (TNF-α) correlate with sleep fragmentation and anxiety severity, indicating an immuno-neuroendocrine interface in disease progression [10,11]. These findings support a systems-level model in which insomnia and anxiety arise from convergent dysregulation of stress-responsive biological networks.

Pharmacological management primarily relies on benzodiazepines, non-benzodiazepine hypnotics, antidepressants, and anxiolytics. While these agents target discrete neurotransmitter systems, long-term use is limited by tolerance, dependence, withdrawal phenomena, cognitive impairment, and altered sleep architecture [12,13]. Furthermore, single-target pharmacotherapy may inadequately address the multifactorial and network-based nature of these disorders. Such limitations have intensified scientific interest in multitarget therapeutic strategies capable of modulating interconnected biological pathways.

Herbal medicine, long utilized within traditional medical systems such as Ayurveda and Traditional Chinese Medicine, is increasingly being investigated within an evidence-based framework. The World Health Organization acknowledges the extensive global reliance on traditional and complementary medicine for mental health and stress-related disorders [14]. Botanical therapeutics possess intrinsic polypharmacological properties due to the presence of structurally diverse phytoconstituents—including alkaloids, flavonoids, terpenoids, lignans, and phenolic acids—which interact synergistically with multiple molecular targets [15].

Mechanistic studies suggest that several medicinal plants exert anxiolytic and sedative effects through modulation of GABA_A receptor activity, attenuation of HPA axis hyperactivity, regulation of monoaminergic transmission, and suppression of inflammatory mediators. For example, Withania somnifera has demonstrated cortisol-lowering, anxiolytic, and sleep-enhancing effects in randomized controlled trials, potentially mediated through adaptogenic modulation of stress pathways [16]. Valeriana officinalis and Passiflora incarnata have shown affinity for GABAergic systems, contributing to reduced sleep latency and anxiety scores [17,18]. Similarly, Matricaria chamomilla exhibits mild anxiolytic and anti-inflammatory effects, potentially mediated by flavonoid interactions with central benzodiazepine receptors [19]. These multitarget interactions align conceptually with network pharmacology approaches, positioning phytotherapy as a systems-based intervention.

Despite promising findings, heterogeneity in extraction methods, phytochemical standardization, dosage regimens, and study quality limits definitive clinical translation. Moreover, mechanistic pathways remain incompletely characterized, and large-scale, high-quality randomized controlled trials are still required to substantiate efficacy and safety profiles [20]. Therefore, a critical, evidence-based synthesis integrating molecular mechanisms, preclinical findings, and clinical outcomes is essential.

The present review aims to provide an expanded, mechanistically grounded evaluation of phytotherapeutic interventions for insomnia and mental stress. By integrating traditional knowledge with contemporary pharmacological evidence, this work seeks to elucidate therapeutic potential, identify research gaps, and propose future directions for translational development in botanical neuropsychopharmacology.

Below is your expanded Ph.D.-level section (≈5 journal pages equivalent) written in IJNPR-style scientific tone, with analytical depth, mechanistic discussion, and integrated evidence synthesis. Content is structured but avoids excessive subheading fragmentation to maintain publication flow.

2. MAJOR HERBAL MEDICINES FOR INSOMNIA AND ANXIETY

Phytotherapeutic agents traditionally used for insomnia and anxiety are increasingly supported by mechanistic and clinical evidence. Unlike single-target synthetic drugs, medicinal plants contain structurally diverse bioactive compounds capable of modulating interconnected neuroendocrine, neurotransmitter, and inflammatory pathways. The following sections critically evaluate major botanicals with substantial experimental and clinical evidence.

2.1 Withania somnifera

Family: Solanaceae
Traditional System: Ayurveda
Principal Phytoconstituents: Withanolides, sitoindosides, alkaloids
Pharmacological Profile

Ashwagandha is widely classified as an adaptogen—an agent that enhances nonspecific resistance to stress while normalizing physiological functions. Preclinical and clinical studies attribute multiple neuropsychopharmacological properties to standardized root extracts, including anxiolytic, anti-inflammatory, antioxidant, neuroprotective, and sleep-enhancing effects.

Mechanistic Insights

The primary mechanism underlying its anti-stress and sleep-promoting effects involves modulation of the hypothalamic–pituitary–adrenal (HPA) axis. Chronic stress leads to sustained cortisol elevation, which disrupts circadian rhythm and sleep architecture. Ashwagandha has been shown to significantly reduce serum cortisol levels, thereby attenuating stress-induced hyperarousal.

Additionally, withanolides appear to modulate GABAergic signaling pathways, enhancing inhibitory neurotransmission and reducing neuronal excitability. Experimental models suggest potential interaction with GABA_A receptor complexes, although the precise binding affinity remains under investigation.

Ashwagandha also exhibits antioxidant and anti-inflammatory properties, reducing reactive oxygen species and pro-inflammatory cytokines implicated in stress-related neurodegeneration. These combined effects support a systems-level therapeutic action rather than isolated receptor targeting.

Clinical Evidence

Randomized, double-blind, placebo-controlled trials have demonstrated:

- Significant reduction in Perceived Stress Scale (PSS) scores
- Decreased serum cortisol concentrations
- Improvement in sleep onset latency and sleep quality indices
- Reduction in anxiety severity scores

Clinical benefits appear particularly pronounced in stress-induced insomnia and chronic stress disorders, where HPA-axis dysregulation predominates. Safety profiles indicate good tolerability with minimal adverse effects at standardized doses (typically 300–600 mg/day extract).

2.2 Valeriana officinalis

Family: Caprifoliaceae

Active Compounds: Valerenic acid, valepotriates, sesquiterpenes

Pharmacological Profile

Valerian is one of the most extensively studied herbal sedatives. Traditionally used in European phytotherapy, it demonstrates sedative-hypnotic, mild anxiolytic, and muscle relaxant properties.

Mechanistic Insights

The therapeutic action of valerian is primarily mediated through modulation of the GABAergic system. Valerenic acid inhibits GABA transaminase, reducing GABA degradation and increasing synaptic GABA availability. Additionally, valerian enhances binding affinity at GABA_A receptors, producing inhibitory effects comparable, though milder, than benzodiazepines.

Unlike benzodiazepines, valerian does not appear to significantly alter REM sleep architecture, suggesting a potentially safer long-term sleep profile.

Clinical Evidence

Meta-analyses and controlled trials report modest but statistically significant improvements in:

- Sleep latency
- Sleep efficiency
- Subjective sleep quality

Effects are more pronounced in individuals with mild to moderate insomnia rather than severe chronic insomnia. Valerian is commonly recommended for short-term management of sleep disturbances and situational anxiety.

2.3 Passiflora incarnata

Family: Passifloraceae

Active Constituents: Flavonoids (e.g., chrysin), harmala alkaloids

Pharmacological Profile

Passionflower functions as a mild sedative and anxiolytic, frequently used for nervous restlessness, insomnia, and stress-related tension.

Mechanistic Insights
Flavonoid constituents such as chrysin are proposed to interact with central benzodiazepine receptors, modulating GABAergic transmission. Additionally, passionflower may increase central GABA levels by inhibiting enzymatic breakdown, thereby reducing neural hyperexcitability.
Preclinical models suggest additional modulation of monoaminergic systems, although this requires further confirmation in human trials.
Clinical Evidence
Clinical studies indicate anxiolytic efficacy comparable to low-dose benzodiazepines in mild anxiety disorders, with fewer cognitive side effects and lower risk of dependence. Improvements have been reported in preoperative anxiety and generalized anxiety symptoms, along with enhanced subjective sleep quality.

2.4 Bacopa monnieri
Family: Plantaginaceae
Traditional Use: Ayurvedic nootropic
Active Constituents: Bacosides A and B
Pharmacological Profile
Bacopa monnieri is traditionally classified as a medhya rasayana (cognitive rejuvenator) in Ayurveda. Modern research supports its nootropic, anxiolytic, neuroprotective, and antioxidant properties.
Mechanistic Insights
Bacosides enhance serotonergic transmission and modulate cholinergic systems, contributing to improved cognitive function and mood stabilization. Additionally, Bacopa reduces oxidative stress by enhancing endogenous antioxidant enzymes such as superoxide dismutase and catalase.
Neuroplasticity-enhancing effects have been observed through increased dendritic branching and synaptic signaling in experimental models, supporting long-term cognitive and emotional resilience.
Clinical Evidence
Human trials report:
- Reduction in anxiety scores
- Improved memory retention and cognitive processing
- Enhanced stress tolerance

Unlike sedative herbs, Bacopa exerts gradual neuromodulatory effects, making it particularly relevant in chronic stress–associated cognitive impairment and anxiety-related insomnia.

2.5 Matricaria chamomilla
Family: Asteraceae
Active Compound: Apigenin
Pharmacological Profile
Chamomile is widely used as a mild tranquilizer and sleep inducer. It also exhibits anti-inflammatory and antioxidant properties.
Mechanistic Insights
Apigenin binds selectively to benzodiazepine receptors within the GABA_A receptor complex, enhancing inhibitory neurotransmission without producing strong sedative or amnestic effects. Chamomile's anti-inflammatory properties may additionally contribute to improved sleep by reducing cytokine-mediated arousal mechanisms.
Clinical Evidence
Randomized trials demonstrate improvement in generalized anxiety symptoms and mild insomnia. Chamomile appears particularly beneficial in individuals with subclinical anxiety and sleep disturbances, offering favorable tolerability and minimal adverse reactions.

2.6 Rhodiola rosea
Family: Crassulaceae
Active Constituents: Rosavins, salidroside
Rhodiola is classified as an adaptogen with anti-fatigue and stress-modulating properties. It regulates HPA-axis activity and reduces stress-induced cortisol release [21]. Preclinical studies demonstrate modulation of monoaminergic neurotransmission, particularly serotonin and dopamine pathways [22].

Clinical trials report reductions in fatigue, stress symptoms, and mild anxiety, indirectly contributing to improved sleep quality [23].

2.7 Ocimum sanctum
Family: Lamiaceae
Active Compounds: Eugenol, ursolic acid
Holy basil exhibits anxiolytic, anti-inflammatory, and antioxidant properties. It modulates stress responses through cortisol reduction and enhances resilience to psychological stress [24]. Clinical data suggest improvement in generalized anxiety symptoms and stress-associated insomnia [25].

2.8 Lavandula angustifolia
Family: Lamiaceae
Active Constituents: Linalool, linalyl acetate
Lavender essential oil demonstrates anxiolytic and sedative properties via modulation of GABAergic neurotransmission and voltage-gated calcium channels [26]. Randomized controlled trials indicate efficacy in generalized anxiety disorder and sleep disturbances [27].

2.9 Melissa officinalis
Family: Lamiaceae
Active Compounds: Rosmarinic acid, citral
Lemon balm enhances GABA activity by inhibiting GABA transaminase [28]. Clinical studies show reductions in anxiety scores and improvements in sleep latency and restlessness [29].

2.10 Piper methysticum
Family: Piperaceae
Active Constituents: Kavalactones
Kava exerts anxiolytic effects through modulation of GABA_A receptors and inhibition of voltage-gated sodium and calcium channels [30]. Meta-analyses suggest significant improvement in anxiety symptoms; however, hepatotoxicity concerns require careful monitoring [31].

2.11 Ziziphus jujuba
Family: Rhamnaceae
Active Constituents: Jujubosides
Traditionally used in Traditional Chinese Medicine for insomnia, jujube enhances GABAergic transmission and exhibits sedative-hypnotic activity in experimental models [32]. Clinical data suggest improved sleep duration and reduced sleep fragmentation [33].

2.12 Ginkgo biloba
Family: Ginkgoaceae
Active Constituents: Ginkgolides, flavonoids
Ginkgo improves cerebral blood flow and exerts antioxidant effects. It may reduce anxiety symptoms via modulation of neurotransmitter systems and oxidative stress pathways [34]. Some clinical studies indicate benefits in stress-related cognitive impairment and mild anxiety [35].

2.13 Panax ginseng
Family: Araliaceae
Active Compounds: Ginsenosides
Panax ginseng acts as an adaptogen, modulating stress hormones and enhancing cognitive performance [36]. It improves fatigue, stress tolerance, and possibly sleep regulation in stress-induced conditions [37].

2.14 Hypericum perforatum
Family: Hypericaceae
Active Constituents: Hypericin, hyperforin

Primarily known for antidepressant activity, St. John's Wort modulates serotonin, dopamine, and norepinephrine pathways [38]. Improvement in mild anxiety and sleep disturbances secondary to depressive symptoms has been reported [39].

2.15 Eschscholzia californica
Family: Papaveraceae
Active Constituents: Alkaloids (protopine)
California poppy exhibits mild sedative and anxiolytic effects through GABAergic modulation [40]. Clinical evidence suggests improved sleep quality in mild insomnia [41].

2.16 Scutellaria lateriflora
Family: Lamiaceae
Active Constituents: Baicalin, flavonoids
Skullcap possesses anxiolytic properties linked to GABA_A receptor interaction and antioxidant activity [42]. Preliminary human studies indicate reduced anxiety scores [43].

2.17 Centella asiatica
Family: Apiaceae
Active Constituents: Asiaticoside, triterpenoids
Centella asiatica exhibits anxiolytic and neuroprotective effects through antioxidant mechanisms and modulation of monoaminergic pathways [44]. Clinical data suggest reduced stress and enhanced cognitive clarity [45].

2.18 Humulus lupulus
Family: Cannabaceae
Active Constituents: Xanthohumol, humulone
Hops has sedative properties and is often combined with valerian. It enhances GABAergic activity and improves sleep onset latency [46].

2.19 Magnolia officinalis
Family: Magnoliaceae
Active Constituents: Honokiol, magnolol
Magnolia bark exhibits anxiolytic and sedative effects through GABA_A receptor modulation and cortisol suppression [47]. Experimental studies demonstrate reduced stress-induced behavioral changes [48].

2.20 Crocus sativus
Family: Iridaceae
Active Constituents: Crocin, safranal
Saffron modulates serotonergic pathways and exhibits anxiolytic and antidepressant properties [49]. Clinical trials suggest improvement in sleep quality and reduction in anxiety symptoms [50].

Integrative Interpretation
Collectively, these 20 botanicals demonstrate mechanistic convergence across:
- HPA-axis modulation
- GABAergic enhancement
- Monoaminergic regulation
- Anti-inflammatory effects
- Antioxidant neuroprotection

This multi-target interaction profile reinforces the suitability of phytotherapeutics for complex neuropsychiatric conditions such as insomnia and anxiety, where single-pathway pharmacotherapy may be insufficient.

3.COMPREHENSIVE COMPARATIVE EVIDENCE TABLE

Plant	Primary Action	Key Bioactive Compounds	Major Mechanism	Clinical Evidence Strength
Withania somnifera	Adaptogen	Withanolides	HPA-axis modulation, ↓ cortisol	Strong RCT evidence
Valeriana officinalis	Sedative	Valerenic acid	GABA-A receptor modulation	Moderate meta-analysis support
Passiflora incarnata	Anxiolytic	Flavonoids (chrysin)	GABA enhancement	Moderate clinical support
Bacopa monnieri	Nootropic/anxiolytic	Bacosides	Serotonergic modulation, antioxidant	Moderate RCT evidence
Matricaria chamomilla	Mild sedative	Apigenin	Benzodiazepine receptor binding	Moderate clinical evidence
Rhodiola rosea	Adaptogen	Rosavins	Monoamine modulation, HPA regulation	Moderate evidence
Ocimum sanctum	Anti-stress	Eugenol	Cortisol reduction	Emerging clinical evidence
Lavandula angustifolia	Anxiolytic	Linalool	GABA modulation	Strong RCT evidence
Melissa officinalis	Calming	Rosmarinic acid	GABA transaminase inhibition	Moderate evidence
Piper methysticum	Potent anxiolytic	Kavalactones	GABA-A interaction	Strong but safety concerns
Ziziphus jujuba	Hypnotic	Jujubosides	GABAergic enhancement	Moderate evidence
Ginkgo biloba	Neuroprotective	Ginkgolides	Antioxidant, monoamine modulation	Limited–moderate evidence
Panax ginseng	Adaptogen	Ginsenosides	Stress hormone regulation	Moderate evidence
Hypericum perforatum	Antidepressant/anxiolytic	Hyperforin	Serotonin reuptake inhibition	Strong (depression-related)
Eschscholzia californica	Mild sedative	Alkaloids	GABAergic activity	Limited–moderate
Scutellaria lateriflora	Anxiolytic	Baicalin	GABA-A interaction	Preliminary evidence
Centella asiatica	Anxiolytic/nootropic	Asiaticoside	Antioxidant, monoamine modulation	Emerging evidence
Humulus lupulus	Sedative	Xanthohumol	GABA modulation	Moderate adjunct evidence

Plant	Primary Action	Key Bioactive Compounds	Major Mechanism	Clinical Evidence Strength
Magnolia officinalis	Anxiolytic	Honokiol	GABA-A, cortisol suppression	Experimental + early clinical
Crocus sativus	Anxiolytic	Crocin	Serotonergic modulation	Moderate RCT support

4. SAFETY, TOXICOLOGY, AND HERB–DRUG INTERACTIONS

Herbal medicines employed for the management of insomnia and anxiety are generally considered safe when administered within recommended therapeutic ranges. However, their increasing integration into psychiatric and sleep medicine necessitates systematic evaluation of safety, toxicological profiles, and potential herb–drug interactions. Although phytotherapeutics are often perceived as inherently safe because of their natural origin, biologically active secondary metabolites may exert clinically significant pharmacological effects, particularly when combined with conventional psychotropic medications. Concerns related to standardization, regulatory oversight, and adverse event monitoring have been highlighted in recent reviews [51], [52].

Clinical investigations of Withania somnifera demonstrate good tolerability at standardized doses (300–600 mg/day of root extract). Mild gastrointestinal discomfort, nausea, and transient somnolence are the most commonly reported adverse effects. Randomized controlled trials have not demonstrated serious toxicity, although isolated reports suggest possible thyroid-stimulating effects, warranting caution in hyperthyroid individuals [53].

Valeriana officinalis has been extensively studied for insomnia. Meta-analytic evidence indicates a favorable safety profile, with occasional reports of headache, dizziness, gastrointestinal upset, and mild daytime drowsiness [54]. Unlike benzodiazepines, valerian has not been consistently associated with dependence or withdrawal syndromes. Rare hepatotoxicity reports remain inconclusive and require further pharmacovigilance data.

The safety of Matricaria chamomilla has been confirmed in randomized trials evaluating generalized anxiety disorder. Adverse reactions are uncommon but may include allergic responses in individuals sensitive to Asteraceae species [55]. Due to coumarin-like constituents, theoretical interaction with anticoagulant therapy has been proposed.

Clinical data for Bacopa monnieri indicate minimal toxicity in controlled studies. Gastrointestinal disturbances such as nausea and increased bowel movements are the most frequently reported adverse events [56].

Similarly, Passiflora incarnata exhibits a favorable safety profile in anxiety management. Sedation and mild dizziness have been reported, but serious adverse events are rare in clinical trials [57].

Herb–drug interactions represent a significant clinical concern. Sedative botanicals may exert additive pharmacodynamic effects when combined with benzodiazepines, non-benzodiazepine hypnotics, antihistamines, opioids, or other CNS depressants. Such combinations may enhance sedation and impair psychomotor performance, particularly in elderly individuals [52], [58].

Pharmacokinetic interactions may occur through modulation of cytochrome P450 enzymes. Although most anxiolytic and hypnotic herbs demonstrate minimal CYP450 inhibition at therapeutic doses, variability in extract composition may alter drug metabolism pathways, particularly CYP3A4 and CYP2D6, thereby influencing plasma concentrations of co-administered psychotropic agents [52], [58].

Special populations require cautious evaluation. Elderly patients are at increased risk of sedation-related falls and drug interactions due to polypharmacy. Pregnancy and lactation safety data remain insufficient for most herbs discussed, and routine use cannot be recommended without professional supervision [59]. Pediatric use similarly lacks robust long-term safety evidence.

Quality control is a critical determinant of safety. Variability in phytochemical content, contamination with heavy metals or pesticides, and adulteration may influence toxicity profiles. Implementation of Good Manufacturing Practices and standardized extract formulations is essential to ensure consistent therapeutic outcomes [51], [59].

In conclusion, herbal medicines used for insomnia and anxiety exhibit generally favorable tolerability with low incidence of severe adverse effects when appropriately prescribed. Nonetheless, clinicians must remain vigilant regarding herb–drug interactions, patient comorbidities, and product quality. Continued pharmacovigilance and high-quality clinical trials are required to strengthen the safety evidence base for phytotherapeutic interventions in mental health care [60].

5. LIMITATIONS OF CURRENT EVIDENCE

Despite growing scientific interest in phytotherapeutic interventions for insomnia and anxiety, the current body of evidence presents several methodological and clinical limitations that restrict definitive conclusions regarding efficacy, safety, and standardization. While preclinical studies and small-scale clinical trials demonstrate promising anxiolytic and sedative effects, heterogeneity in study design, phytochemical composition, and outcome measurement limits the generalizability of findings. A critical appraisal of these limitations is essential for contextualizing existing results and guiding future research directions [61].

One of the most significant challenges in herbal medicine research is variability in phytochemical standardization. Botanical preparations often differ in extraction methods, plant parts used, geographical origin, harvesting conditions, and processing techniques. These factors significantly influence the concentration of bioactive constituents such as withanolides, valerenic acid, flavonoids, and bacosides. For example, different extracts of Withania somnifera may contain widely varying withanolide concentrations, leading to inconsistent pharmacological effects across studies. Similarly, variability in valerenic acid content in Valeriana officinalis preparations can affect sedative potency. The absence of universally accepted standardization guidelines complicates cross-trial comparison and meta-analytic interpretation [62], [63].

In addition to compositional variability, many clinical trials investigating herbal medicines for insomnia and anxiety are characterized by small sample sizes. Numerous randomized controlled trials enroll fewer than 100 participants, thereby limiting statistical power and increasing the likelihood of type II error. Small cohorts also reduce the ability to detect rare adverse events and diminish the robustness of subgroup analyses. Consequently, while preliminary findings may suggest efficacy, confirmatory large-scale multicenter trials remain scarce. Systematic reviews frequently emphasize the need for adequately powered studies to validate early positive findings [64].

Another major limitation concerns the scarcity of long-term safety data. Most trials assessing botanical interventions are conducted over relatively short durations, typically ranging from 4 to 12 weeks. Chronic insomnia and anxiety disorders, however, often require prolonged management. The absence of extended follow-up periods limits understanding of sustained efficacy, cumulative toxicity, withdrawal phenomena, and potential interactions emerging over time. Although short-term tolerability appears favorable for herbs such as Bacopa monnieri and Passiflora incarnata, long-term pharmacovigilance data remain insufficient [65]. This gap restricts their integration into evidence-based chronic psychiatric care frameworks.

Inconsistent dosing regimens further complicate evidence interpretation. Clinical studies frequently employ varying extract concentrations, capsule strengths, dosing frequencies, and treatment durations. For example, standardized extracts of ashwagandha may be administered at 250 mg, 300 mg, or 600 mg daily across different trials, while valerian dosages range broadly from 300 mg to 900 mg before bedtime. Such heterogeneity precludes establishment of definitive therapeutic dosing guidelines. Furthermore, few studies perform dose–response analyses, limiting understanding of optimal effective and safe dosage ranges [62], [66]. Without standardized dosing parameters, translation of clinical research findings into routine practice remains challenging.

Outcome measurement variability also contributes to evidentiary limitations. Insomnia and anxiety are assessed using diverse psychometric instruments, including the Pittsburgh Sleep Quality Index (PSQI), Insomnia Severity Index (ISI), Hamilton Anxiety Rating Scale (HAM-A), and Perceived Stress Scale (PSS). While these scales are validated, inconsistent selection across trials hinders comparative evaluation. Moreover, reliance on subjective self-reported measures without objective sleep assessments such as polysomnography or actigraphy reduces precision in determining true physiological sleep improvements [67].

Publication bias represents another important concern. Positive findings demonstrating significant anxiolytic or hypnotic effects are more likely to be published than neutral or negative results. This

selective reporting may overestimate therapeutic efficacy in systematic reviews and meta-analyses. Funnel plot asymmetry and limited availability of unpublished data have been observed in analyses of herbal interventions for anxiety disorders, suggesting potential reporting bias [64], [68]. Such distortion may contribute to inflated expectations regarding botanical efficacy.

Methodological weaknesses are also evident in aspects of randomization, allocation concealment, and blinding procedures. Herbal preparations often possess distinctive tastes and odors, which may compromise blinding integrity in placebo-controlled trials. Inadequate reporting of randomization methods further affects risk-of-bias assessments. Consequently, some studies are classified as having moderate to high methodological bias, reducing confidence in reported outcomes [61], [64].

Another limitation involves limited mechanistic correlation between clinical outcomes and biological biomarkers. Although preclinical studies demonstrate modulation of GABAergic, serotonergic, and hypothalamic–pituitary–adrenal (HPA) axis pathways, few clinical trials concurrently measure biochemical markers such as cortisol, inflammatory cytokines, or neurotransmitter metabolites. Integration of clinical endpoints with mechanistic biomarkers would strengthen causal inference and translational relevance [63], [69].

Population heterogeneity further restricts generalizability. Many studies recruit relatively healthy individuals experiencing mild stress rather than patients diagnosed with moderate-to-severe generalized anxiety disorder or chronic insomnia. This limits extrapolation to clinical psychiatric populations. Additionally, data from geriatric, pediatric, pregnant, and comorbid populations remain limited, leaving important demographic gaps in the evidence base [65].

Regulatory disparities across countries present an additional challenge. Herbal medicines are regulated as dietary supplements in some regions and as medicinal products in others. This inconsistency affects quality assurance, labeling standards, and post-marketing surveillance. Variability in regulatory frameworks may indirectly influence trial quality and reproducibility [62], [70].

Finally, limited head-to-head comparisons with standard pharmacotherapy restrict understanding of relative effectiveness. Most studies compare herbal preparations to placebo rather than to first-line agents such as cognitive behavioral therapy for insomnia (CBT-I), selective serotonin reuptake inhibitors (SSRIs), or benzodiazepines. Direct comparative trials are necessary to clarify whether phytotherapeutics are best positioned as monotherapy for mild conditions or as adjunctive treatments within integrative care models [61], [66].

In summary, although herbal medicines demonstrate promising anxiolytic and sleep-enhancing properties, current evidence is constrained by phytochemical variability, small sample sizes, limited long-term safety data, inconsistent dosing regimens, methodological heterogeneity, and potential publication bias. Addressing these limitations through large-scale, well-designed randomized controlled trials, standardized extract formulations, biomarker integration, and transparent reporting practices is essential to strengthen the scientific foundation of phytotherapy for insomnia and anxiety disorders [61]–[70].

6. FUTURE RESEARCH DIRECTIONS AND CLINICAL INTEGRATION

Despite encouraging preliminary evidence supporting herbal medicines for insomnia and anxiety, future research must adopt more rigorous and translationally oriented methodologies to strengthen the scientific foundation of phytotherapeutic interventions. One of the foremost priorities is the development and utilization of standardized extract formulations with clearly quantified bioactive constituents. Variability in phytochemical composition remains a major barrier to reproducibility and regulatory acceptance. Standardization based on validated chemical markers—such as withanolides, valerenic acid, flavonoids, and bacosides—would enhance dose precision, inter-study comparability, and mechanistic interpretation [71].

Future investigations should also incorporate biomarker-based outcome measures alongside validated psychometric scales. While subjective improvements in sleep quality and anxiety severity are clinically meaningful, integration of biological markers such as serum cortisol, inflammatory cytokines (e.g., IL-6, TNF-α), C-reactive protein, and autonomic parameters (heart rate variability) would provide objective evidence of physiological modulation. Given the established role of hypothalamic–pituitary–adrenal (HPA) axis dysregulation and neuroinflammation in stress-related disorders, biomarker-driven trials may clarify mechanistic pathways and identify responder subgroups [72], [73].

Large-scale, multicenter randomized controlled trials (RCTs) are critically needed to overcome limitations of small sample sizes and single-center bias. Such trials should employ robust randomization procedures, adequate blinding strategies, standardized dosing regimens, and long-term follow-up periods. Extended safety evaluations are particularly important for chronic insomnia and generalized anxiety disorder, conditions often requiring sustained management. Longitudinal pharmacovigilance systems and post-marketing surveillance studies would further strengthen safety data [71], [74].

Comparative effectiveness research represents another essential direction. Most existing trials compare herbal medicines to placebo rather than to standard pharmacotherapies such as benzodiazepines, non-benzodiazepine hypnotics, or selective serotonin reuptake inhibitors (SSRIs). Direct head-to-head comparisons would clarify whether phytotherapeutics are best positioned as first-line options for mild conditions, adjunctive therapies, or alternatives for patients intolerant to synthetic agents. Furthermore, evaluation of synergistic polyherbal formulations—commonly employed in traditional systems such as Ayurveda and Traditional Chinese Medicine—may reveal additive or complementary mechanisms of action targeting multiple neurobiological pathways simultaneously [75].

Translational integration of molecular pharmacology, phytochemistry, and clinical psychiatry is essential for advancing the field. Multi-omics approaches, receptor-binding assays, and neuroimaging studies may elucidate central nervous system targets and pharmacodynamic profiles. Bridging preclinical findings with clinical endpoints will enhance mechanistic credibility and regulatory confidence [72], [75].

From a clinical perspective, herbal medicines may be rationally integrated into mental health care frameworks under evidence-based supervision. They are particularly suitable as adjunctive therapy alongside psychotherapy, including cognitive behavioral therapy for insomnia (CBT-I), which remains a first-line non-pharmacological intervention. Combination approaches may yield synergistic improvements in sleep latency, sleep maintenance, and anxiety symptom reduction. Phytotherapeutics may also be considered in mild-to-moderate insomnia, stress-related anxiety disorders, or in patients who prefer non-synthetic or integrative treatment modalities. However, individualized assessment, monitoring for herb–drug interactions, and adherence to standardized preparations remain fundamental to safe clinical implementation [73], [74].

In conclusion, advancing research quality, biomarker integration, comparative effectiveness trials, and interdisciplinary collaboration will be crucial for translating herbal medicine from complementary therapy to evidence-informed integrative psychiatry. Continued scientific rigor will determine the extent to which phytotherapeutic agents can be confidently incorporated into mainstream clinical guidelines for insomnia and anxiety management [71]–[75].

7. CONCLUSION

Herbal medicine represents a promising complementary and integrative strategy for the management of insomnia and anxiety disorders, conditions that are highly prevalent and frequently comorbid in modern clinical practice. The growing global burden of stress-related neuropsychiatric disorders, coupled with limitations associated with conventional pharmacotherapy—such as tolerance, dependence, withdrawal phenomena, and adverse cognitive effects—has intensified interest in phytotherapeutic interventions. Botanical medicines offer a multi-target pharmacological approach that aligns with the complex neurobiological underpinnings of insomnia and anxiety, including dysregulation of the hypothalamic–pituitary–adrenal (HPA) axis, impaired GABAergic inhibition, altered serotonergic signaling, and neuroinflammatory processes.

Evidence from preclinical and clinical studies indicates that several medicinal plants exert meaningful anxiolytic and sleep-promoting effects. For instance, Withania somnifera demonstrates adaptogenic and cortisol-lowering properties, enhancing stress resilience and improving sleep quality. Valeriana officinalis acts primarily through modulation of GABA-A receptors, supporting sleep initiation and maintenance. Passiflora incarnata enhances inhibitory neurotransmission and reduces neural hyperexcitability, contributing to its mild anxiolytic profile. Similarly, Bacopa monnieri exerts neuroprotective and serotonergic modulatory effects that may alleviate anxiety symptoms while supporting cognitive function. Matricaria chamomilla, through apigenin-mediated benzodiazepine receptor interaction, provides gentle tranquilizing and sleep-inducing benefits.

Collectively, these botanicals illustrate the principle of polypharmacology, wherein multiple bioactive constituents interact with diverse molecular targets, potentially offering broader therapeutic coverage

compared to mono-receptor synthetic agents. Clinical findings, although variable in magnitude, consistently suggest benefits in mild-to-moderate insomnia and stress-related anxiety disorders, particularly when used as adjunctive therapy alongside established non-pharmacological interventions such as cognitive behavioral therapy for insomnia (CBT-I). Importantly, most herbal medicines discussed exhibit favorable short-term tolerability and low risk of dependency when administered in standardized doses.

However, despite encouraging evidence, several limitations prevent definitive clinical recommendations. Variability in phytochemical standardization, small sample sizes, short trial durations, and inconsistent dosing regimens reduce the strength of current conclusions. Long-term safety data remain insufficient for chronic psychiatric use, and robust head-to-head comparisons with conventional pharmacotherapy are limited. Additionally, regulatory disparities and quality control issues may influence therapeutic consistency and safety profiles.

Therefore, while herbal medicine holds considerable promise as an integrative modality for insomnia and anxiety management, its widespread incorporation into clinical guidelines requires rigorous scientific validation. Future research must prioritize large-scale multicenter randomized controlled trials, biomarker-driven outcome measures, standardized extract formulations, and long-term pharmacovigilance assessments.

In conclusion, phytotherapeutic agents represent a scientifically plausible and clinically relevant adjunct in the multidisciplinary management of sleep and anxiety disorders. With continued methodological refinement and translational research integration, herbal medicine may evolve from complementary support to evidence-informed component of personalized mental health care.

REFERENCES

1. Morin CM, Benca R. Chronic insomnia. Lancet. 2012;379(9821):1129–1141.
2. American Psychiatric Association. Diagnostic and Statistical Manual of Mental Disorders. 5th ed. Arlington (VA): American Psychiatric Publishing; 2013.
3. Bandelow B, Michaelis S. Epidemiology of anxiety disorders in the 21st century. Dialogues Clin Neurosci. 2015;17(3):327–335.
4. Alvaro PK, Roberts RM, Harris JK. A systematic review assessing bidirectionality between sleep disturbances, anxiety, and depression. Sleep. 2013;36(7):1059–1068.
5. Riemann D, Spiegelhalder K, Feige B, et al. The hyperarousal model of insomnia: A review of the concept and its evidence. Sleep Med Rev. 2010;14(1):19–31.
6. Vgontzas AN, Tsigos C, Bixler EO, et al. Chronic insomnia and activity of the stress system: A preliminary study. J Psychosom Res. 1998;45(1–2):21–31.
7. McEwen BS. Stress, adaptation, and disease: Allostasis and allostatic load. Ann N Y Acad Sci. 1998;840:33–44.
8. Nutt DJ, Malizia AL. New insights into the role of the GABA(A)-benzodiazepine receptor in psychiatric disorder. Br J Psychiatry. 2001;179:390–396.
9. Monti JM, Monti D. The involvement of serotonin in sleep regulation and disorders. Sleep Med Rev. 2000;4(2):100–124.
10. Irwin MR. Why sleep is important for health: A psychoneuroimmunology perspective. Annu Rev Psychol. 2015;66:143–172.
11. Dowlati Y, Herrmann N, Swardfager W, et al. A meta-analysis of cytokines in major depression. Biol Psychiatry. 2010;67(5):446–457.
12. Glass J, Lanctôt KL, Herrmann N, et al. Sedative hypnotics in older people with insomnia: Meta-analysis of risks and benefits. BMJ. 2005;331(7526):1169.
13. Holbrook AM, Crowther R, Lotter A, et al. Meta-analysis of benzodiazepine use in insomnia. CMAJ. 2000;162(2):225–233.
14. World Health Organization. WHO Global Report on Traditional and Complementary Medicine 2019. Geneva: WHO; 2019.
15. Wagner H. Multitarget therapy—The future of treatment for more than just functional dyspepsia. Phytomedicine. 2006;13(Suppl 5):122–129.
16. Chandrasekhar K, Kapoor J, Anishetty S. A prospective, randomized double-blind, placebo-controlled study of safety and efficacy of a high-concentration full-spectrum extract of Withania somnifera root in reducing stress and anxiety. Indian J Psychol Med. 2012;34(3):255–262.

17. Bent S, Padula A, Moore D, et al. Valerian for sleep: A systematic review and meta-analysis. Am J Med. 2006;119(12):1005–1012.
18. Miyasaka LS, Atallah AN, Soares BG. Passiflora incarnata for anxiety disorder. Cochrane Database Syst Rev. 2007;(1):CD004518.
19. Amsterdam JD, Li Y, Soeller I, et al. A randomized, double-blind, placebo-controlled trial of oral chamomile extract therapy for generalized anxiety disorder. J Clin Psychopharmacol. 2009;29(4):378–382.
20. Sarris J, McIntyre E, Camfield DA. Plant-based medicines for anxiety disorders, part 1: A review of preclinical studies. CNS Drugs. 2013;27(3):207–219.
21. Panossian A, Wikman G. Effects of adaptogens on the central nervous system and molecular mechanisms associated with their stress-protective activity. Pharmaceuticals (Basel). 2010;3(1):188–224.
22. Amsterdam JD, Panossian AG. Rhodiola rosea as a putative botanical antidepressant. Phytomedicine. 2016;23(7):770–783.
23. Darbinyan V, Aslanyan G, Amroyan E, et al. Clinical trial of Rhodiola rosea in stress-induced fatigue. Phytomedicine. 2000;7(5):365–371.
24. Cohen MM. Tulsi – Ocimum sanctum: A herb for all reasons. J Ayurveda Integr Med. 2014;5(4):251–259.
25. Saxena RC, Singh R, Kumar P, et al. Evaluation of anti-stress activity of Ocimum sanctum. J Ethnopharmacol. 2012;143(3):761–767.
26. Cavanagh HMA, Wilkinson JM. Biological activities of lavender essential oil. Phytother Res. 2002;16(4):301–308.
27. Kasper S, Gastpar M, Müller WE, et al. Lavender oil preparation in generalized anxiety disorder. Int J Neuropsychopharmacol. 2010;13(5):629–639.
28. Awad R, Levac D, Cybulska P, et al. Effects of lemon balm on mood and cognition. Mediterr J Nutr Metab. 2009;2(1):27–34.
29. Cases J, Ibarra A, Feuillère N, et al. Pilot trial of Melissa officinalis extract on stress and insomnia. Med J Nutrition Metab. 2011;4:211–218.
30. Sarris J, Stough C, Bousman CA, et al. Kava in anxiety disorders: Double-blind RCT. J Clin Psychopharmacol. 2013;33(5):643–648.
31. Pittler MH, Ernst E. Kava extract for anxiety: Meta-analysis. Cochrane Database Syst Rev. 2003;(1):CD003383.
32. Shergis JL, Zhang AL, Zhou W, et al. Ziziphus for insomnia: Systematic review. Sleep Med Rev. 2013;17(6):463–470.
33. Jiang JG, Huang XJ, Chen J, et al. Sedative and hypnotic effects of jujube. J Ethnopharmacol. 2007;110(3):421–426.
34. Diamond BJ, Bailey MR. Ginkgo biloba: Indications and safety. J Psychiatr Res. 2013;47(2):121–130.
35. Woelk H, Arnoldt KH, Kieser M, et al. Ginkgo biloba in generalized anxiety disorder. J Psychiatr Res. 2007;41(6):472–480.
36. Reay JL, Scholey AB, Kennedy DO. Panax ginseng and cognitive performance. Psychopharmacology (Berl). 2010;212(3):345–356.
37. Kim HG, Cho JH, Yoo SR, et al. Panax ginseng for stress reduction: Systematic review. J Ginseng Res. 2013;37(1):8–15.
38. Butterweck V. Mechanism of action of St John's Wort. Pharmacopsychiatry. 2003;36(Suppl 3):S113–S118.
39. Linde K, Berner MM, Kriston L. St John's Wort for major depression. Cochrane Database Syst Rev. 2008;(4):CD000448.
40. Rolland A, Fleurentin J, Lanhers MC, et al. Behavioural effects of Eschscholzia californica. Planta Med. 2001;67(7):658–663.
41. Hanus M, Lafon J, Mathieu M. Double-blind study of California poppy in mild insomnia. Phytother Res. 2004;18(7):565–568.
42. Awad R, Muhammad A, Durst T, et al. Bioactive flavonoids in skullcap. Phytomedicine. 2003;10(8):640–649.

43. Brock C, Whitehouse J, Tewfik I, et al. American skullcap in mood disorders. Phytother Res. 2014;28(5):692–698.
44. Brinkhaus B, Lindner M, Schuppan D, et al. Chemical, pharmacological and clinical profile of Centella asiatica. Phytomedicine. 2000;7(5):427–448.
45. Wattanathorn J, Mator L, Muchimapura S, et al. Centella asiatica in anxiety and cognition. J Ethnopharmacol. 2008;116(2):325–332.
46. Franco L, Sánchez C, Bravo R, et al. Sedative effects of hops. Acta Physiol Hung. 2012;99(2):133–139.
47. Kuribara H, Kishi E, Hattori N, et al. Honokiol reduces stress response. Pharmacol Biochem Behav. 2000;67(4):743–749.
48. Xu Q, Yi LT, Pan Y, et al. Antidepressant-like effects of magnolol. Eur J Pharmacol. 2008;597(1–3):124–131.
49. Lopresti AL, Hood SD, Drummond PD. Saffron in psychiatric disorders. Hum Psychopharmacol. 2014;29(6):517–527.
50. Shafiee M, Arekhi S, Omranzadeh A, et al. Crocus sativus for anxiety and sleep disorders: Meta-analysis. J Affect Disord. 2018;227:243–251.
51. Bent S. Herbal medicine in the United States: review of efficacy, safety, and regulation. J Gen Intern Med. 2008;23(6):854–859.
52. Posadzki P, Watson L, Ernst E. Herb–drug interactions: an overview of systematic reviews. Br J Clin Pharmacol. 2013;75(3):603–618.
53. Chandrasekhar K, Kapoor J, Anishetty S. A prospective, randomized double-blind, placebo-controlled study of high-concentration full-spectrum extract of Withania somnifera root in reducing stress and anxiety. Indian J Psychol Med. 2012;34(3):255–262.
54. Fernández-San-Martín MI, Masa-Font R, Palacios-Soler L, et al. Effectiveness of Valeriana officinalis on insomnia: a meta-analysis of randomized placebo-controlled trials. Sleep Med. 2010;11(6):505–511.
55. Amsterdam JD, Li Y, Soeller I, Rockwell K, Mao JJ, Shults J. A randomized, double-blind, placebo-controlled trial of oral chamomile extract therapy for generalized anxiety disorder. J Clin Psychopharmacol. 2009;29(4):378–382.
56. Kongkeaw C, Dilokthornsakul P, Thanarangsarit P, Limpeanchob N, Scholfield CN. Meta-analysis of randomized controlled trials on cognitive effects of Bacopa monnieri extract. J Ethnopharmacol. 2014;151(1):528–535.
57. Miyasaka LS, Atallah AN, Soares BGO. Passiflora incarnata L. for anxiety disorder. Cochrane Database Syst Rev. 2007;(1):CD004518.
58. Izzo AA, Ernst E. Interactions between herbal medicines and prescribed drugs: an updated systematic review. Drugs. 2009;69(13):1777–1798.
59. Ekor M. The growing use of herbal medicines: issues relating to adverse reactions and challenges in monitoring safety. Front Pharmacol. 2014;4:177.
60. Sarris J, McIntyre E, Camfield DA. Plant-based medicines for anxiety disorders, part 2: a review of clinical studies with supporting preclinical evidence. CNS Drugs. 2013;27(4):301–319.
61. Sarris J, Panossian A, Schweitzer I, Stough C, Scholey A. Herbal medicine for depression, anxiety and insomnia: a review of psychopharmacology and clinical evidence. Eur Neuropsychopharmacol. 2011;21(12):841–860.
62. Heinrich M, Barnes J, Gibbons S, Williamson EM. Fundamentals of Pharmacognosy and Phytotherapy. 2nd ed. Edinburgh: Churchill Livingstone; 2012.
63. Panossian A, Wikman G. Effects of adaptogens on the central nervous system and molecular mechanisms associated with their stress-protective activity. Pharmaceuticals (Basel). 2010;3(1):188–224.
64. Fernández-San-Martín MI, Masa-Font R, Palacios-Soler L, et al. Effectiveness of Valeriana officinalis on insomnia: a meta-analysis of randomized placebo-controlled trials. Sleep Med. 2010;11(6):505–511.
65. Sarris J, McIntyre E, Camfield DA. Plant-based medicines for anxiety disorders, part 1: a review of preclinical studies. CNS Drugs. 2013;27(3):207–219.
66. Bent S, Padula A, Moore D, Patterson M, Mehling W. Valerian for sleep: a systematic review and meta-analysis. Am J Med. 2006;119(12):1005–1012.

67. Buysse DJ, Reynolds CF III, Monk TH, Berman SR, Kupfer DJ. The Pittsburgh Sleep Quality Index: a new instrument for psychiatric practice and research. Psychiatry Res. 1989;28(2):193–213.
68. Egger M, Davey Smith G, Schneider M, Minder C. Bias in meta-analysis detected by a simple graphical test. BMJ. 1997;315(7109):629–634.
69. McEwen BS. Protective and damaging effects of stress mediators: central role of the brain. Dialogues Clin Neurosci. 2006;8(4):367–381.
70. Ekor M. The growing use of herbal medicines: issues relating to adverse reactions and challenges in monitoring safety. Front Pharmacol. 2014;4:177.
71. Sarris J, McIntyre E, Camfield DA. Plant-based medicines for anxiety disorders, part 2: a review of clinical studies with supporting preclinical evidence. CNS Drugs. 2013;27(4):301–319.
72. Panossian A, Wikman G. Effects of adaptogens on the central nervous system and the molecular mechanisms associated with their stress-protective activity. Pharmaceuticals (Basel). 2010;3(1):188–224.
73. McEwen BS. Protective and damaging effects of stress mediators: central role of the brain. Dialogues Clin Neurosci. 2006;8(4):367–381.
74. Qaseem A, Kansagara D, Forciea MA, Cooke M, Denberg TD. Management of chronic insomnia disorder in adults: a clinical practice guideline from the American College of Physicians. Ann Intern Med. 2016;165(2):125–133.
75. Williamson EM. Synergy and other interactions in phytomedicines. Phytomedicine. 2001;8(5):401–409.